ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Modern partnerships with CROs
In this article in Contract Pharma, ICON SMEs share insight on strategic and blended outsourcing models and trends in today’s market.
Driving progress in reducing kit wastage
This article explores how shifting to more reliable kit forecasting can help reduce waste, cost and logistical requirements.
Integration of AI in imaging clinical trials
This article explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials.
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
Considerations for safety data migration methods
This article explains how to handle the different types of data migration methods and how companies can select the optimum approach to ensure data integrity is maintained.
Beyond the glass: A look at digital pathology’s practical applications and novel possibilities in clinical trials
This article looks at practical uses of digital pathology technologies and illustrates considerations for their use in global clinical trials.
AI In Clinical Research: Now And Beyond
In this piece from Forbes, Dr. Greg Licholai, Chief Medical and Chief Innovation Officer talks about the promising future of AI in clinical research.
ICON interview: Insights on the new EMA guidelines for computerised systems and electronic data in clinical trials
Vesta Marciulioniene shares her insights on the new EMA guideline for computerised systems and electronic data in clinical trials.
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.